The new InnoviGene™ Suite from Thermo Fisher Scientific is an all-in-one, browser-based platform that offers a suite of Sanger sequencing applications to enable regulatory compliance while increasing ...
Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing
Ginkgo Bioworks, Inc. (“Ginkgo”) which is building the leading platform for cell programming and biosecurity, and Virica Biotech Inc. (“Virica”), a leading developer of enhancers for scaling of viral ...
2| To prepare the calcium phosphate–DNA coprecipitate, combine 100 μl of 2.5 M CaCl 2 with 25 μg of plasmid DNA in a sterile ... in tap water. Graham, F.L. & van der Eb, A.J. A new technique ...
Propranolol reduces experimental murine cerebral cavernous malformations (CCMs) and prevents embryonic caudal venous plexus (CVP) lesions in zebrafish that follow mosaic inactivation of ccm2. Because ...
In this important study, the authors used a zebrafish model and scRNAseq analysis to show that a subset of keratinocytes within melanoma microenvironment highly up-regulate Twist and undergo ...
The Inducement Option Grants have an exercise price per share equal to the closing price of Imunon's common stock as reported by Nasdaq on October 7, 2024. The Inducement Option Grants have a 10-year ...
Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin ® ...
Considering the importance of researching the bacteriological quality of seafood, the following study aimed to make a brief overview on the occurrence of Escherichia coli in marine fish and shellfish, ...
COVID-19 during pregnancy is associated with higher risk of maternal disease severity and/or death, characterized by a ...
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiencyLONDON and NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx ...
Like Ford Motor (NYSE: F), Toyota is scaling back its EV plans as already a month ago, Investing.com reported that Toyota is scaling back its EV production plans for 2026 by as much as 30%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback